NPS Pharmaceuticals, Inc.

  • The Profitable Business of Developing Orphan Drugs

    By Kanak Kanti - June 4, 2013 | Tickers: ALXN, NPSP, SNY

    "Making every patient count" is a catchy phrase that is perhaps most meaningful for biotech companies like NPS Pharmaceuticals (NASDAQ: NPSP) who are in the business of developing orphan drugs. The simple reason – they cannot afford to lose a single patient just because there aren’t too many of them. Their whole business is centered around producing drugs for rare diseases that bigger pharma often does not address, and in more »

  • PDL BioPharma – Promising Profitable Pauper?

    By Karl Ege - June 3, 2013 | Tickers: NPSP, PRXL, PDLI


    Growth & dividend play shedding negative equity image

    PDL BioPharma (NASDAQ: PDLI) is a pioneer biotech company with a patented process to create humanized antibodies. The company engages in the management of antibody humanization patents, royalty assets and license agreements with various biotechnology and pharmaceuticals companies.

    From 2008 to 20012, revenue and net income increased to $374 million from $294 million (+27%) with net income jumping to $212 million from $68 more »

  • Double-Digit Returns from the Biotechnology Strategy

    By Jeff Stouffer - May 7, 2013 | Tickers: NPSP, REGN, SNY, XBI, THRX, VRTX

    Investments in biotechnology by the average investor tend to deliver hit or miss returns over time. Since inception, the SPDR S&P Biotech ETF (NYSEMKT: XBI) has delivered double-digit returns. This ETF holds 53 stocks and is focused on this industry. Created on Jan. 31, 2006, the one-year return is 33.76%, the three-year return is 23.57%, and the five-year return is 13.27%. Only the one-month and three-month more »

  • Looking For Solid Science in Biotech

    By Streetwise Reports - March 5, 2012 | Tickers: AZN, AVNR, GILD, HGSI, NPSP, VRTX

    George S. Mack, The Life Sciences Report

     Solid ideas in biotech come from solid research.

    I first spoke with Analyst Carol Werther in early 1999 when I was preparing to write about Immunex which had developed Enbrel (etanercept) for rheumatoid arthritis (RA). The product had just been approved by the FDA in November 1998, and it held the distinction of being the first in a new class of anti-tumor necrosis more »

  • Columbia Labs Fails to Impress FDA

    By Brandy Betz - January 21, 2012 | Tickers: ACT, CBRX, NPSP

    Columbia Laboratories (NASDAQ: CBRX) failed to impress an FDA advisory committee with the efficacy of its 8% progesterone gel intended to prevent preterm pregnancy in women with short cervixes. The committee, which convened late Friday afternoon, voted 13-4 against recommending the gel for approval. Though trading of its stock was paused during the meeting, Columbia still managed to fall roughly 67% thanks to extended trading.

    Columbia and marketing partner Watson more »

  • NPS Pharm. Gets "Buy" Recommendation, Heads for Conference

    By Brandy Betz - January 6, 2012 | Tickers: NPSP

    Small cap NPS Pharmaceuticals (NASDAQ: NPSP), scheduled to appear next week at the JP Morgan Healthcare Conference, has received another 'Buy' recommendation from Needham & Company with a price target of $15.00.  The company has several novel therapeutics in the pipeline that include Gattex, a short bowl syndrome (SBS) treatment whose New Drug Application (NDA) was submitted to the FDA in December, and Natpara (NPS558), a Phase 3 hypoparathyroidism treatment more »